These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7175442)

  • 1. Human melanoma antigen AH is an autoantigenic ganglioside related to GD2.
    Watanabe T; Pukel CS; Takeyama H; Lloyd KO; Shiku H; Li LT; Travassos LR; Oettgen HF; Old LJ
    J Exp Med; 1982 Dec; 156(6):1884-9. PubMed ID: 7175442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganglioside GM2 as a human tumor antigen (OFA-I-1).
    Tai T; Paulson JC; Cahan LD; Irie RF
    Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5392-6. PubMed ID: 6193515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient.
    Yamaguchi H; Furukawa K; Fortunato SR; Livingston PO; Lloyd KO; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1990 May; 87(9):3333-7. PubMed ID: 2159145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.
    Vrionis FD; Wikstrand CJ; Fredman P; Månsson JE; Svennerholm L; Bigner DD
    Cancer Res; 1989 Dec; 49(23):6645-51. PubMed ID: 2479468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant antibodies against ganglioside expressed on tumor cells.
    Hanai N; Nakamura K; Shitara K
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human monoclonal antibody to ganglioside GD2-inhibited human melanoma xenograft.
    Katano M; Jien M; Irie RF
    Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1053-9. PubMed ID: 6540688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
    Livingston PO; Natoli EJ; Calves MJ; Stockert E; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1987 May; 84(9):2911-5. PubMed ID: 3472242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human monoclonal antibody to tumor-associated ganglioside GD2.
    Katano M; Saxton RE; Irie RF
    J Clin Lab Immunol; 1984 Nov; 15(3):119-26. PubMed ID: 6099419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganglioside antigens in tissue sections of skin, naevi, and melanoma--implications for treatment of melanoma.
    Hersey P
    Cancer Treat Res; 1991; 54():137-51. PubMed ID: 1673856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human monoclonal antibody to tumor-associated ganglioside GD2: suppressed growth of human melanoma in nude mice.
    Katano M; Irie RF
    Immunol Lett; 1984; 8(4):169-74. PubMed ID: 6542067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ganglioside vaccines with emphasis on GM2.
    Livingston P
    Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.
    Livingston PO; Ritter G; Srivastava P; Padavan M; Calves MJ; Oettgen HF; Old LJ
    Cancer Res; 1989 Dec; 49(24 Pt 1):7045-50. PubMed ID: 2582446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.
    Cahan LD; Irie RF; Singh R; Cassidenti A; Paulson JC
    Proc Natl Acad Sci U S A; 1982 Dec; 79(24):7629-33. PubMed ID: 6296843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluctuations in the expression of a glycolipid antigen associated with differentiation of melanoma cells monitored by a monoclonal antibody, Leo Mel 3.
    Werkmeister JA; Triglia T; Mackay IR; Dowling JP; Varigos GA; Morstyn G; Burns GF
    Cancer Res; 1987 Jan; 47(1):225-30. PubMed ID: 3791209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes.
    Riemer AB; Förster-Waldl E; Brämswig KH; Pollak A; Zielinski CC; Pehamberger H; Lode HN; Scheiner O; Jensen-Jarolim E
    Eur J Immunol; 2006 May; 36(5):1267-74. PubMed ID: 16568495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of glycolipids.
    Portoukalian J
    Clin Rev Allergy Immunol; 2000 Aug; 19(1):73-8. PubMed ID: 11064828
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity.
    Thurin J; Thurin M; Kimoto Y; Herlyn M; Lubeck MD; Elder DE; Smereczynska M; Karlsson KA; Clark WM; Steplewski Z
    Cancer Res; 1987 Mar; 47(5):1229-33. PubMed ID: 3815333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues.
    Brezicka T; Bergman B; Olling S; Fredman P
    Lung Cancer; 2000 Apr; 28(1):29-36. PubMed ID: 10704706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity of adriamycin-containing immunoliposomes targeted with anti-ganglioside monoclonal antibodies.
    Ohta S; Igarashi S; Honda A; Sato S; Hanai N
    Anticancer Res; 1993; 13(2):331-6. PubMed ID: 8517645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells.
    Lloyd KO; Gordon CM; Thampoe IJ; DiBenedetto C
    Cancer Res; 1992 Sep; 52(18):4948-53. PubMed ID: 1516051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.